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Abstract Myokymia is characterized by spontaneous,
involuntary muscle fiber group contraction visible as
vermiform movement of the overlying skin. Myokymia
with episodic ataxia is a rare, autosomal dominant trait
caused by mutations in KCNA1, encoding a voltage-gated
potassium channel. In the present study, we report a family
with four members affected with myokymia. Additional
clinical features included motor delay initially diagnosed as
cerebral palsy, worsening with febrile illness, persistent
extensor plantar reflex, and absence of epilepsy or episodic
ataxia. Mutation analysis revealed a novel c.676C>A
substitution in the potassium channel gene KCNA1,
resulting in a T226K nonconservative missense mutation
in the Kv1.1 subunit in all affected individuals. Electro-
physiological studies of the mutant channel expressed in
Xenopus oocytes indicated a loss of function. Co-expres-
sion of WT and mutant cRNAs significantly reduced
whole-oocyte current compared to expression of WT
Kv1.1 alone.
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Introduction
Myokymia is defined as spontaneous involuntary muscle
fiber group contraction, is visible as vermiform movement
of the overlying skin, and may be hereditary or acquired.
Electromyography (EMG) shows continuous motor unit
activity with spontaneous discharges of high intraburst
frequency. Myokymia occurs in autoimmune disease with
antibodies to voltage-gated potassium channel subunits in
Isaacs–Merton syndrome and Morvan fibrillary chorea [1].
Hereditary myokymia with episodic ataxia type 1 (OMIM
#160120) arises from mutations in the voltage-gated
potassium channel KCNA1 [2]. The ataxia is characterized
by profound attacks of cerebellar ataxia lasting seconds to
minutes. Partial epilepsy has been reported in some families
with KCNA1-associated disease [3, 4]. Another rare cause
of myokymia with neonatal epilepsy but lacking episodic
Neurogenetics (2007) 8:131–135
DOI 10.1007/s10048-006-0071-z
H. Chen: C. von Hehn:L. K. Kaczmarek
Department of Pharmacology,
Yale University School of Medicine,
New Haven, CT, USA
H. Chen
e-mail: Haijun.chen@yale.edu
C. von Hehn
e-mail: Christian.vonhehn@yale.edu
L. K. Kaczmarek
e-mail: Leonard.kaczmarek@yale.edu
L. R. Ment
Department of Pediatrics, Yale University School of Medicine,
New Haven, CT, USA
e-mail: laura.ment@yale.edu
L. R. Ment
Department of Neurology, Yale University School of Medicine,
New Haven, CT, USA
F. M. Hisama (*)
Division of Genetics, Harvard Medical School,
Boston, MA, USA
e-mail: fuki.hisama@childrens.harvard.edu
B. R. Pober
Department of Surgery, Harvard Medical School,
Boston, MA, USA
e-mail: Barbara.pober@childrens.harvard.edu
F. M. Hisama
Division of Genetics, Children’s Hospital Boston,
300 Longwood Avenue Fegan 10,
Boston, MA 02115, USAataxia results from a KCNQ2 potassium channel mutation
[5]. Reduced frequency and severity of myokymia and
episodic ataxia have been reported after treatment with
acetazolamide or carbamazepine [3, 6].
Approximately a dozen missense mutations and one
truncating mutation in KCNA1 have been reported [3, 4, 7–
10]. The functional consequences of human KCNA1
mutations causing typical myokymia and EA1 have been
reported [11], much less is known about the functional
consequences of mutations causing unusual KCNA1-asso-
ciated phenotypes.
In the present study, we describe the clinical and genetic
features of a new family with hereditary myokymia lacking
epilepsy or episodic ataxia. Molecular studies of KCNA1 in
the proband revealed a c.676C>A transversion resulting in
the substitution of Lys for Thr at codon 226 (T226K) and a
c.1355A>C transversion resulting in Y452S. Further
genetic studies showed that all affected family members
carried the T226K mutation, which was absent in unaffect-
ed family members and ethnically matched normal controls,
whereas the Y452S substitution was present in both
affected and unaffected family members and normal
controls. In transfected mammalian cells, electrophysiolog-
ic studies demonstrated functional effects of the c.676C>A
transversion with no currents above background levels
recorded from oocytes injected with the mutant subunit.
Co-injection of the wild-type and mutant cRNAs produced
significantly smaller whole-oocyte currents than injection
with the WT cRNA alone.
Materials and methods
Clinical data
The family pedigree is shown in Fig. 1. Six family
members (two unaffected and four affected) were available
for clinical and genetic studies approved by the Yale
Human Investigations Committee.
Subject II-1
The proband, a 13-year-old boy (II-1), was the product of
an unremarkable pregnancy and delivery. He was diagnosed
with cerebral palsy because of leg stiffness and delayed
walking at 18 months old. Cognitive development was
normal; his medical history was significant for esotropia. At
4 years old, he was hospitalized with increasing leg pain,
stiffness, and inability to walk during the course of a flu-
like illness. Creatine kinase (CK) was elevated at 520 U/
l acutely (normal <195 U/l), but was normal when repeated
interictally. Examination showed periorbital myokymia,
mild abdominal and leg muscle hypertrophy, leg stiffness,
spastic gait, hyperreflexia, and bilateral Babinski sign.
Magnetic resonance imaging (MRI) of the brain and spine
were normal. Metabolic studies including electrolytes,
amino and organic acids, carnitine, ammonia, lactate, and
thyroid functions were normal. Routine studies of cerebral
spinal fluid and an electroencephalogram were normal.
Needle EMG of deltoid and iliopsoas muscles showed
irregular, polyphasic continuous motor unit discharges with
normal interference pattern.
Additional family members
Six family members were evaluated. Four affected mem-
bers (mother and three sons) had myokymia on clinical
examination, EMG examination, or both. Nerve conduction
velocities were normal. There was no history of seizures or
episodic ataxia in any of them. The mother (I-2, Fig. 1)i sa
40-year-old woman who had had muscle twitching since
childhood, hyperreflexia, bilateral Babinski sign, and
tendency to run on her toes. Her husband is unaffected
and had a normal neurological exam. A 12-year-old son
(II-2) also had delayed walking, leg stiffness, and was
diagnosed with cerebral palsy. At age 3 years, he had an
episode of prolonged generalized paralysis with no muscle
response to tetanic stimulation after general anesthesia for
esotropia surgery. He recovered within 1 day. MRI of the
brain and spine were normal. An 8-year-old daughter (II-3)
is unaffected. A 5-year-old son (II-4) had symptoms
identical to his brothers and was hospitalized twice for
episodes of increased muscle stiffness with presumed viral
gastroenteritis, elevated CK during both episodes (606 U/
l and 997 U/l) but had normal CKs measured while well.
Fig. 1 Family pedigree. Squares indicate males, circles indicate
females. Blackened symbols denote individuals with myokymia.
Alleles at codon 226 are indicated (Thr = wild-type, Lys = mutation)
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of muscle symptoms in three of the brothers who remain
asymptomatic. The mother, with milder symptoms, de-
clined treatment. Three family members with myokymia
had esotropia; one patient required three eye surgeries.
Molecular studies
Genomic DNAwas extracted from blood samples or buccal
swabs. The coding region of the single-exon 1,448-bp gene
KCNA1 (GenBank sequence NM_000217) was amplified.
Polymerase chain reactions (PCRs) were performed in a
25-μl reaction volume containing 50 ng genomic DNA,
50 ng of each primer, 1.5 mM MgCl2, 200 μM dNTPs, 1×
PCR buffer (Finnzyme), and 2.5 U of Finnzyme using a
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA). Cycling parameters consisted of a modified
touchdown (stepdown) protocol as follows: an initial hot
start denaturation at 94°C for 5 min (hot start); 94°C for
45 s, annealing temperature (three cycles each at 70, 67, 64,
61,and 58°C) for 45 s, and extension at 72°C for 2 min for
a total of 15 cycles followed by 25 cycles of 94°C for 45 s,
55°C for 45 s, 72°C for 1 min; a final extension step of
72°C for 10 min followed by a 4°C hold. PCR products
were separated by electrophoresis on a 1% agarose gel and
visualized by ethidium bromide staining. PCR products
were purified by spin column (Qiagen, Valencia, CA) or by
enzymatic method (ExoSAP-IT, USB, Cleveland, OH) and
analyzed for mutations by automated sequencing (Applied
Biosystems, Foster City, CA). The c.1355A>C transversion
resulted in the creation of a DdeI restriction site, so the
presence of the sequence variant was tested by sequencing
and confirmed with restriction digest in all subjects.
Restriction digests were performed with DdeI( N e w
England Biolabs, Beverly, MA) at 37°C for 2 h.
Oocyte expression and electrophysiological studies
Human Kv1.1 cDNA was subcloned into Kpn1 and HindIII
sites of psGEM. The Kv1.1-T226K mutation was intro-
duced by site-directed mutagenesis and confirmed by
automated sequencing. cRNAs were synthesized using an
mMessage mMachine kit (Ambion, Austin, TX) and
quantified by spectroscopy.
Oocytes were isolated from Xenopus laevis and defolli-
culated by collagenase treatment. Each oocyte was injected
with either 5 ng of human Kv1.1-WT, 5 ng Kv1.1-T226K,
or 2.5 ng WT plus 2.5 ng T226K cRNA. Whole-oocyte
currents were measured with two electrode voltage clamp
techniques (Oocyte Clamp, Warner Instruments, Hamden,
CT) with constant perfusion (1 ml/min, solution
exchange\3 s) after 16 h. Data were sampled at 1 kHz
and filtered at 0.25 kHz. Standard bath solution was ND-96
(in mM): 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, and 5
HEPES/NaOH, pH 7.5.
Results
Mutation analysis of KCNA1
Mutation analysis of KCNA1 identified two sequence
variants: a c.676C>A transversion resulting in the substitu-
tion of Lys for Thr at codon 226 (T226K) and a c.1355A>C
transversion resulting in Y452S and creating a DdeI
restriction site. Either a Tyr (NM_000217) or a Ser
(AAI01734) had been reported at codon 452, but the
population frequency and association with disease were
unknown. Therefore, we tested all six family members
(four affected, two unaffected) and 10 normal controls for
the SNP and found that all 16 subjects were homozygous
for the Y452S substitution, compatible with a common
polymorphism. In contrast, all (4/4) affected subjects were
heterozygous for the previously unreported T226K mis-
sense mutation, which was absent in both unaffected family
members and absent in 190 chromosomes from ethnically
matched normal controls (Fig. 2).
Electrophysiological studies of the human Kv1.1 mutant The
genetic studies of the segregation of the T226K mutation
favored it as a pathological mutation, but given that two
missense mutations were identified, we sought additional
supporting evidence. We tested whether the missense
mutation alters human Kv1.1 channel function by express-
ing Kv1.1-T226K in Xenopus oocytes. No currents above
background levels were recorded from Kv1.1-T226K
cRNA-injected oocytes, whereas Kv1.1 wild-type channels
produced typical delayed rectifier currents (Fig. 3). We then
mimicked the heterozygous situation by co-injecting equal
amounts of Kv1.1 WT and T226K mutant cRNAs. Co-
injection produced significantly smaller whole-oocyte cur-
rents than injection with Kv1.1 WT cRNA alone (Fig. 3c
and d). These results indicate that the T226K mutation
significantly reduced efflux of potassium ions during
depolarization and is therefore likely to result in increased
muscle cell excitability.
Discussion
Mutations in KCNA1 are typically associated with episodic
ataxia type 1 (EA1), characterized by profound cerebellar
ataxia lasting seconds to minutes and interictal myokymia
[6]. The expanded phenotypic spectrum associated with
proven KCNA1 mutation includes a family with prolonged
Neurogenetics (2007) 8:131–135 133episodes of episodic ataxia and epilepsy, but without
myokymia [12]. Other families have been reported with
myokymia and adducted thumbs, congenital contractures,
kyphoscoliosis, or epilepsy with myokymia [4, 7–10]. We
report a family with autosomal dominant myokymia
lacking either ataxia or epilepsy. The mother had self-
described lifelong “muscle twitchiness” but never sought
medical attention for her condition until the hospitalizations
of her sons. Myokymia in the periorbital region and on
EMG were the features that led to genetic studies of
KCNA1.
Although the stiffness, toe walking, and esotropia could
be caused by continuous muscle contraction, the extensor
plantar reflex [observed on multiple exams by experienced
two neurologists (LRM and FMH)] is a new finding for
KCNA1-associated disease and suggests involvement of the
corticospinal tract. The KCNA1 knockout mouse has been
reported to exhibit altered inhibition of layer V pyramidal
neocortical neurons [13].
KCNA1 on chromosome 12p13 encodes Kv1.1, a
potassium channel subunit. Delayed-rectifier voltage-
gated-type potassium channels are important in the rapid
neuronal repolarization after an action potential and are
multimeric proteins containing four subunits around a
central pore. The Kv1.1 potassium channel subunit is
expressed during development in neuronal and glial cells
in the central and peripheral nervous systems [14]. Kv1.1
plays an important role in regulating neuronal excitability
in the central nervous system, as shown by studies of the
KCNA1 knockout mouse with an increased susceptibility to
seizures [15].
The present family has generalized myokymia due to a
T226K mutation in the voltage-gated potassium channel
KCNA1. Unusual clinical features include pyramidal
dysfunction and worsening with febrile illness or anaesthe-
sia. One previously reported 3-year-old boy presented in a
similar fashion to our patients with a 12-h episode of
inability to walk, increased tone, and elevated CK during a
febrile illness [3]. No anesthesia exposure was reported.
That child had a P244H mutation in the intracellular loop
between transmembrane segments 2 and 3. The whole-cell
current amplitudes elicited by injection of P244H did not
Fig. 2 Sequence chromatograms demonstrating c.676C>A resulting
in T226K substitution in KCNA1. A DNA sequence from an affected
patient (I-2) heterozygous for the mutation (top) and from a normal
control (bottom) are presented
Fig. 3 Missense mutation T226K induces loss of function of human
Kv1.1 channels expressed in Xenopus oocytes. a–c Representative
family of whole-oocyte currents recorded from oocytes expressing
human Kv1.1-WT (a), Kv1.1-T226K (b), and both Kv1.1 WT and
T226K (c). Currents were evoked by a series of 350-ms test pulses
from −80 to +60 mV in 10-mV increments from a hold potential of
−90 mV. Tail currents were recoded at −40 mV. Scale bar, 100 ms and
1 μA. d I–V curves for three experimental conditions in a–c. Data
were collected for 10–15 oocytes in each group. The peak currents in
a and c are significantly different at test voltages between 0 and
+60 mV (P<0.05)
134 Neurogenetics (2007) 8:131–135differ from wild-type amplitudes. Co-injection of P244H
plus an equal amount of wild-type cRNA yielded a peak
current amplitude that was 200% of wild-type alone.
We identified a novel, nonconservative T226K missense
mutation that is located in the second transmembrane
domain of Kv1.1 and is invariant from Drosophila
melanogaster to mice and humans [6]. In contrast to the
functional effects reported for the P244H mutation, heter-
ologous expression of the T226K mutation identified in the
present family showed that the mutant potassium channel
expressed in oocytes demonstrated no current above
background levels, and its co-expression with the wild-type
channel significantly reduced whole-oocyte current, com-
patible with a severe effect of the mutation. The T226K
mutation is likely to reduce efflux of potassium ions during
depolarization, thereby increasing cellular excitability. The
phenotypic similarity between the P244H and the T226K
mutations contrasts with their biophysical effects. There-
fore, additional factors must contribute to the functional
effects of these mutations. Kv1.1 forms heteromeric
channels with other subunits and interacts with other
accessory subunits [16]. In addition to their well-known
role as ion channels that regulate neuronal firing, potassium
channels have also been shown to activate enzymes linked
to intracellular signaling pathways [16, 17]. One of these
novel interactions may contribute to differences in the
manifestation of disease-causing mutations.
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